An HSCI/Harvard iLab collaboration promotes entrepreneurship

Over the course of this academic year we have been collaborating with the iLab at the Harvard Business School to promote what we are pleased to report is an ever increasing entrepreneurial spirit within the HSCI community. An HSCI-iLab series of workshops focused on key issues faced by entrepreneurs provides broad perspectives and practical guidance to scientists at all levels of career development, and also gives them with an opportunity to network with peers, academic and industry veterans.
Last fall, we organized three highly successful events:
  • Alternative Sources Beyond Traditional Venture Funding with Roger Kitterman, Managing Partner of Partners Innovation Fund, Bill Sahlman, Professor of Business Administration and Senior Associate Dean at Harvard Business School, and Michael Weingarten, Director of NCI SBIR & STTR Programs;
  • Winning Concepts That Attract Life Sciences Investments with Doug Cole, General Partner of Flagship Ventures, Jens Eckstein, President of SR One, and Terry McGuire, Co-Founder and General Partner of Polaris Venture;
  • Starting a Life Sciences Company with Carmichael Roberts, Partner of North Bridge Venture Partners.
This spring, we have two events:
  • Steps from Startup Idea to Launching A Company with Derrick Rossi, Principal Faculty member of HSCI and Co-founder of Moderna Therapeutics;
  • Finding Your Career Path as An Academic, An Entrepreneur, or A Hybrid with Joshua Boger, Executive Chairman at Alkeus Pharmaceuticals, Founder and former CEO of Vertex Pharmaceuticals; Stuart Orkin, Professor of Pediatrics, Harvard Medical School and Howard Hughes Medical Institute; Chair, Pediatric Oncology Dana-Farber Cancer Institute; Associate Chief, Division of Hematology/Oncology, Children’s Hospital Boston; and Timothy Springer, Professor, Harvard Medical School, Founder of Leukosite and Scholar Rock.
Our ongoing collaboration with Harvard Business School also includes a roundtable entitled, Advancing the Role of Non-Profit Organizations in Drug Development, which is co-sponsored by the Multiple Myeloma Research Foundation, scheduled for May 19th.